Phase II trial of fenretinide in advanced renal carcinoma
dc.contributor.author | Vaishampayan, Ulka | en_US |
dc.contributor.author | Heilbrun, Lance K. | en_US |
dc.contributor.author | Parchment, Ralph E. | en_US |
dc.contributor.author | Jain, Vikash | en_US |
dc.contributor.author | Zwiebel, James | en_US |
dc.contributor.author | Boinpally, Ramesh R. | en_US |
dc.contributor.author | LoRusso, Patricia M. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.date.accessioned | 2006-09-11T15:51:48Z | |
dc.date.available | 2006-09-11T15:51:48Z | |
dc.date.issued | 2005-01 | en_US |
dc.identifier.citation | Vaishampayan, Ulka; Heilbrun, Lance K.; Parchment, Ralph E.; Jain, Vikash; Zwiebel, James; Boinpally, Ramesh R.; LoRusso, Patricia; Hussain, Maha; (2005). "Phase II trial of fenretinide in advanced renal carcinoma." Investigational New Drugs 23(2): 179-185. <http://hdl.handle.net/2027.42/45264> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45264 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15744595&dopt=citation | en_US |
dc.description.abstract | Purpose : Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal cancer. Methods : Eligibility included unresectable or metastatic renal cell carcinoma (RCC), adequate organ function and Zubrod performance status ≦2. Prior immunotherapy and a maximum of one prior chemotherapy regimen were allowed. Fenretinide was administered at a dose of 900 mg/m 2 twice daily orally for 7 days in a 21-day cycle. Toxicity was assessed at the start of each cycle, and response every 2 cycles. Results : Nineteen eligible patients enrolled of which fifteen had visceral/bone metastases. Seventeen patients had prior nephrectomy and 11 had prior immunotherapy. 76 cycles of therapy were delivered. Therapy was very well tolerated with few severe toxicities consisting of thrombosis in 1 individual and grade 3 fatigue, nausea and diarrhea in 1 patient. 5 patients had grade 2 nyctalopia and 3 patients had transient grade 2 visual toxicity. No objective responses were noted. Stable disease was seen in seven of nineteen cases (37%, 90% C.I. 0.21–0.59). Median time to progression was 1.5 months and median duration of stable disease was 5.8 months (90% C.I. 3.0–8.4). Median survival was 10 months. Tumor fenretinide levels were obtained in three patients and were in the lower end of the therapeutic range. Conclusion : Fenretinide was well tolerated but demonstrated minimal activity that was consistent with results of intratumoral drug measurements. Strategies are needed that will increase systemic and tumor levels of fenretinide. | en_US |
dc.format.extent | 224740 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science + Business Media, Inc. | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Fenretinide | en_US |
dc.subject.other | N-4-Hydroxyphenyl Retinamide | en_US |
dc.subject.other | Renal Cancer | en_US |
dc.subject.other | Clinical Trial | en_US |
dc.title | Phase II trial of fenretinide in advanced renal carcinoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Internal Medicine and Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Division of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA; Karmanos Cancer Institute, 4th Floor Hudson-Webber Cancer Research Center, 4100 John R Road, Detroit, MI, 48201, USA | en_US |
dc.contributor.affiliationother | Biostatistics Core, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.contributor.affiliationother | Division of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.contributor.affiliationother | Biostatistics Core, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.contributor.affiliationother | National Cancer Institute, Bethesda, MD, USA | en_US |
dc.contributor.affiliationother | Division of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.contributor.affiliationother | Division of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 15744595 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45264/1/10637_2005_Article_5864.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s10637-005-5864-7 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.